Antidepressants: An Avoidable and Solvable Controversy

1. Teicher MH Glod C Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207–10.

2. Louie AK Lewis TB Lannon MD. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435–8.

3. Schatzberg AF Dessain E O'Neil P Katz DL Cole JO. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. J Clin Psychopharmacol 1987;7(suppl 6):44S–9S.

4. Schatzberg AF. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991;52(5 suppl):14–20.

5. Salzman C. Practical considerations in the pharmacologic treatment of depression in the elderly. J Clin Psychiatry 1990;59(1 suppl):40–3.

6. Fichner CG Jobe TH Braun BG. Does fluoxetine have a therapeutic window (letter)? Lancet 1991;338:520–1.

7. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a “therapeutic window”? J Clin Psychiatry 1992;53:272–7.

8. Rakel RE , ed. Conn's current therapy. Philadelphia: WB Saunders Company, 1993.

9. Stewart JW Quitkin FM Klein DF. The pharmacotherapy of minor depression. Am J Psychother 1992;46:23–36.

10. Gram LF . Fluoxetine. N Engl J Med 1994;331:1354–61.

11. McElroy SL Keck PE Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995;56(suppl 2):49–55.

12. Dickinson JG. FDA OKs new drugs that over-dose millions, physician says; FDA replies. Dickinson's FDA Review 2002;9:3,10–5.

13. Wernicke J Dunlop SR Dornseif BE Bosomworth JC Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183–8.

14. Cohen JS. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 2001;161:957–64.

15. Cohen JS. Adverse drug effects, compliance, and the initial doses of antihypertensive drugs recommended by the Joint National Committee vs. the Physicians' Desk Reference. Arch Intern Med 2001;161:880–5.

16. Cohen JS. Do standard doses of frequently prescribed drugs cause preventable adverse effects in women? Am Med Womens Assoc 2002;57:105–10.

17. Lazarou J Pomeranz BH Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–5.

18. Zuger A. Caution: that dose may be too high. New York Times, September 17, 2002. www.nytimes.com (accessed 2002 Sept 17).

19. Herxheimer A. How much drug in the tablet? Lancet 1991;337:346–8.

20. FDA Talk Paper. FDA issues public health advisory on cautions for use of antidepressants in adults and children. US Food and Drug Administration, March 22, 2004. www.fda.gov. (accessed 2004 Apr 12).

21. Gartrell N. A doctor's toxic shock. New York Times, January 4, 2004. www.nytimes.com (accessed 2004 Aug 12).

22. American Medical Association Council on Ethical and Judicial Affairs. Code of medical ethics, 1998–1999 edition. Chicago: American Medical Association.

23. Naranjo CA Busto U Sellers EM Sandor P Ruiz I Roberts EA A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.

24. Lasser KE Alan PD Woolhandler SJ Himmelstein DU Wolfe SM Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215–20.

25. Dickinson JG. New FDA study: antidepressants boots pediatric suicidality. Dickinson's FDA webview, August 5, 2004, www.fdaweb.com (accessed 2004 Aug 12).

26. Jureidini JN Doecke CJ Mansfield PR Haby MM Menkes DB Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328:879–83.